Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinEstablishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testingIdentification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryExpansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.Dual neonate vaccine platform against HIV-1 and M. tuberculosis.The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.The influence of delivery vectors on HIV vaccine efficacyT cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections.Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cellsPotent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.Oral re-vaccination of Eurasian wild boar with Mycobacterium bovis BCG yields a strong protective response against challenge with a field strain.Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells.A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsA phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adultsImmunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.Assessment of immunological markers and booster effects of Ag85B peptides, Ag85B, and BCG in blood of BCG vaccinated children: a preliminary report.CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.Current status of new tuberculosis vaccine in children.Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.Tuberculosis: what we don't know can, and does, hurt us.Boosting BCG to protect against TB.Tuberculosis vaccines in clinical trials.Recent developments in tuberculosis vaccines
P2860
Q22242669-8F7633D6-ECBA-4D24-B46D-FCFB10595B33Q30227121-2F8FA548-1A8B-4560-83A2-8CA45F391E1AQ30945400-B2087971-4A7C-4CD8-B269-78791C05A1F9Q33603206-FB3572F3-6EAB-4072-9C01-1901559B22CAQ33723687-8BF9F4B2-A0EA-48B4-A61A-D03072978182Q33908584-D38C9F22-099D-40D6-BBB0-A00E4A1E51D6Q33950119-51127069-6112-4387-B354-350EDF66C60AQ34077543-708A2D60-261F-4014-8391-1B7C4EAD4D54Q34169888-13ED9CE5-4AD8-4E82-961E-F59A18BEC53FQ34605490-A287486F-1E58-4BD2-89D8-15023854F6D7Q34699088-FE84821B-EA05-43F5-8C59-B07142E74E5DQ35157573-E25766B7-B955-4628-9DAA-6D689E951F50Q35220369-B6FAD1CD-ED73-4B61-B134-24C25BA00E49Q35647253-E2D42042-2CE4-4B62-B65F-DFF17B51013AQ35826779-76C6CAB3-F051-4C4E-8F5C-88B8E82742CAQ35889153-AC44639E-59D7-4FDD-8F44-514FCECCF49BQ36106722-076BE531-525F-4C5B-B12F-FA9F762A19EEQ36547958-6E56C40B-79AA-466B-8D62-EEFB243E12A1Q36811028-517BD7E8-9A9D-4A93-ABB7-D2BD7B018264Q37130796-D905A5B5-9777-46D0-8E4E-813DE10EA8CBQ37335461-922BD9FA-E6DE-48EA-B8FB-4C0BB95763A6Q37403767-27793565-6E66-42C7-BA5F-140BF31F5A81Q37530123-2CCB53F6-176B-4244-847F-0736A7773F8CQ37548692-218086FF-F871-4DBC-938C-04A060CA87F8Q37751647-C83B2A86-CCBF-45B2-A7E0-3F82DF957F1AQ37762830-986B7A77-0108-472E-B20C-C029AECFC414Q37878483-A88D99B6-AD4F-4F19-86B8-F2511E3F7399Q58834925-35511645-B35E-41BF-B45B-B8AB301915E1
P2860
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@ast
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@en
type
label
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@ast
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@en
prefLabel
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@ast
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@en
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of b ...... with a new TB vaccine, MVA85A
@en
P2093
Ansar A Pathan
Clare R Sander
Ian Poulton
Kathryn T Whelan
Nicola C Alder
P2860
P356
10.1371/JOURNAL.PONE.0005934
P407
P577
2009-06-16T00:00:00Z